Calypte acts to comply with FDA warning letter:
This article was originally published in Clinica
Calypte Biomedical is taking action to comply with an FDA warning letter listing significant deviations from Federal regulations in the operation of its newly-acquired plant in Rockville, Maryland. The warning letter was based on inspections of the Rockville plant made in November and December 1998, when it was owned and operated by Cambridge Biotech, a subsidiary of bioMerieux Vitek. Calypte says it has responded in writing to many of points raised by the FDA and is rectifying the remaining issues.
You may also be interested in...
Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.